This is a market analysis and its findings — built from public data (search, AI answers, reviews, video, forums), not a delivered client result. All figures measured from that corpus, July 2026. Observational throughout: it reports what the market says and searches, not medical advice.
One plant, two regulatory worlds
Measure the same category with the same instruments in two countries and the regulatory frame becomes visible in the data. UK cannabis demand splits medical 49% / wellness 47% / recreational 4%. The US splits wellness 53% / recreational 26% / medical 21%. That single contrast drives everything else: what people search for, which products they ask about, who captures the visibility, and what the buying problem actually is.
Four findings
1. The two markets want different things from the same plant. The UK's lead use-case is epilepsy (143K monthly searches — the Epidyolex effect), then anxiety and sleep. The US's lead use-case is sleep, at 1.1M monthly searches — wellness demand at national scale — with epilepsy second (401K) and chemotherapy-related nausea third (128K). Product forms follow: the UK skews creams and drinks (the wellness shelf); the US skews pet CBD (192K) and oils, with flower and vapes running through dispensary channels.
2. Access is gated in the UK, navigated in the US. UK medical cannabis has been legal since 2018 but NHS prescriptions are vanishingly rare — access runs through private clinics, which is why clinic-and-access queries are a top UK demand grouping. The US patient searches how to buy: dispensary locators, medical cards, state-by-state law. Same category, different buying problem: the UK buyer needs reassurance and access; the US buyer needs navigation and selection.
3. In both countries, institutions out-rank commerce. Regulators and health-information sites dominate visibility (UK: gov/NHS 18% + health info 11%; US: health info 19% + gov 11%). The commercial layer differs: Holland & Barrett, CBD brands and private clinics in the UK; dispensary-tech marketplaces (Leafly, Weedmaps) in the US. Branded, clinically-credible authority content is the whitespace on both sides of the Atlantic.
4. The evidence has a licensed core and a wellness periphery — and the market knows it. The credible spine is narrow: Epidyolex (epilepsy), Sativex (MS spasticity), Nabilone (chemo nausea). Around it, a huge wellness conversation runs on thinner evidence — UK regulators state plainly there is "no evidence any form of cannabis is effective in treating anxiety, depression or post-traumatic stress disorder" — while patients report real relief and real harms. That tension between licensed evidence and wellness demand is the market's central content opportunity.
The method, briefly
Seven years (87 months, 2019–2026) of Trends × Ads co-measured monthly demand per keyword, per country; CTR-weighted Search share and AI-answer citation share per domain (4,940 citations measured); 155,012 evidence snippets scored for sentiment, emotional register and voice. Demand and visibility are cleanly per-country; the evidence base is the shared English-language conversation, with country-specific voices pulled out and labelled as such — the study says what is measured and what is shared, explicitly.
Interrogate it yourself
The full two-country corpus is live behind a scoped analyst chatbot: open the cannabis study chatbot — it answers only from the evidence, with quotes.